TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Diagnosis of either Open-Angle Glaucoma or Ocular Hypertension in each eye that require IOP lowering treatment.~Exclusion Criteria:~* Eye surgery (including cataract surgery) and or eye laser surgery within the past 6 months.~* Enrollment in other studies using Bimatoprost SR.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SLT (Primary Eye) / Bim SR 15 µg (Contralateral Eye) (Type: ACTIVE_COMPARATOR): Primary Eye: Selective Laser Trabeculoplasty (SLT) administered on Day 1 followed by up to three Sham Bimatoprost sustained release (Bim SR) administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Sham Bimatoprost SR administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.~Contralateral (Other) Eye: Sham SLT administered on Day 1 followed by up to three Bimatoprost SR 15 μg administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Bimatoprost SR 15 μg administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants enrolled under Protocol Amendment 2 or later.
- Bim SR 15 µg (Primary Eye) / SLT (Contralateral Eye) (Type: EXPERIMENTAL): Primary Eye: Sham SLT administered on Day 1 followed by up to three Bimatoprost SR 15 μg administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Bimatoprost SR 15 μg administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.~Contralateral (Other) Eye: SLT administered on Day 1 followed by up to three Sham Bimatoprost SR administrations at Day 4 (Cycle 1), Weeks 16 (Cycle 2) and 32 (Cycle 3) or two Sham Bimatoprost SR administrations at Day 4 (Cycle 1) and Week 16 (Cycle 2) for participants who were enrolled under Protocol Amendment 2 or later.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Combination Dexmedetomidine Added to Fentanyl-based Intravenous Patient-controlled Analgesia on Nausea Vomiting in Highly Susceptible Patients Undergoing Lumbar Spinal Surgery: Prospective Double Blinded Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. female, non-smoking patient who are 20-65 of age scheduled for elective lumbar spine surgery~Exclusion Criteria:~1. Bradycardia on EKG (45bpm)~2. Atrioventricular conduction disorder~3. Uncontrolled hypertension~4. angina history~5. obesity (BMI ≥ 30 kg/m2)~6. Preoperative administration of opioid~7. Preoperative administration of antiemetics~8. Gastrointestinal disorder history~9. Hepatic or renal disease~10. Pregnant 11. Foreigner

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- dexmedetomidine (Type: EXPERIMENTAL): addition of dexmedetomidine to fentanyl-based intravenous patient controlled analgesia (PCA)
- normal saline (Type: PLACEBO_COMPARATOR): normal saline as a placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Weigh ≥40 kg and ≤125 kg~* documented chronic HCV GT1, GT4, or GT6 infection~* cirrhosis/absence of cirrhosis defined by liver biopsy, Fibroscan, or FibroSure®~* either treatment naïve or PR Null Responder, PR Partial Responder, or PR Prior Relapser~* participant and partner both agree to use at least use at least 2 effective methods of contraception from at least 2 weeks prior to Day 1 and continue until up to 6 months after last dose of study drug, or longer if dictated by local regulations~Exclusion Criteria:~* has evidence of decompensated liver disease~* is coinfected with hepatitis B virus (e.g. hepatitis B surface antigen positive) or human immunodeficiency virus~* history of malignancy ≤5 years prior to signing informed consent, or is under evaluation for other active or suspected malignancy~* has cirrhosis and liver imaging within 6 months of Day 1 showing evidence of hepatocellular carcinoma (HCC) or is under evaluation for HCC~* has any of the following conditions: immunologically-mediated disease, organ transplants other than cornea and hair, poor venous access that precludes routine peripheral blood sampling, history of gastric surgery or malabsorption disorders, or any medical condition requiring, or likely to require, chronic systemic administration of corticosteroids during the course of the trial, history of chronic hepatitis not caused by HCV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Grazoprevir + Elbasvir (Type: EXPERIMENTAL): Participants receive a fixed-dose combination (FDC) tablet of 100 mg grazoprevir and 50 mg elbasvir for 12 weeks, followed by 24 weeks of follow-up.
- SOF + PR (Type: ACTIVE_COMPARATOR): Participants receive SOF (400 mg) combined with PegIntron (1.5 mcg/kg) plus RBV (1000-1200 mg weight-based dose) for 12 weeks, followed by 24 weeks of follow-up.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacotherapy and Psychotherapy in the Treatment of Erectile Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Men diagnosed with erectile dysfunction~* Must be in the age range of 18 to 40 years~* Must be in a stable heterosexual relationship~* Must not be suffering from any medical or psychiatric illness~Exclusion Criteria:~* Men not meeting criteria of diagnosis of erectile dysfunction~* Men not in a heterosexual relationship~* Men above the age of 40 years~* Men diagnosed with any medical or psychiatric illness

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): This arm received pharmacotherapy for erectile dysfunction.
- Group B (Type: EXPERIMENTAL): This arm received cognitive behavior psychotherapy for erectile dysfunction.
- Group C (Type: EXPERIMENTAL): This arm received combined treatment approach.
- Group D (Type: PLACEBO_COMPARATOR): This arm acted as a control group and received placebo or no intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Web-based Pain Self-management for Adolescents With Juvenile Idiopathic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 12-18 years of age (inclusive)~* diagnosed with JIA by a pediatric rheumatologist~* able to speak and read English and/or Spanish~* able to complete online measures~* reporting pain in at least one joint over the past 6 months~Exclusion Criteria:~* have another chronic medical condition that adversely impacts pain and/or health-related quality of life (e.g., inflammatory bowel disease, fibromyalgia, cancer, genetic disorder, pervasive developmental disorder, diabetes)~* have a significant cognitive impairment or illiteracy that would prevent understanding of the intervention and outcome measures~* currently in psychotherapy

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Web-based coping skills training (Type: EXPERIMENTAL): Involves completion of a 12-week interactive, multi-component, multimedia online training that consists of instruction in specific self-management strategies, disease education, and social support.
- Online disease education (Type: ACTIVE_COMPARATOR): Involves viewing 12 educational websites about Juvenile Idiopathic Arthritis over the course of 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study on the Effect of Granisetron on Myofascial Pain in the Orofacial Muscles

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age ≥ 18 years~* a diagnosis of myofascial pain according to the research diagnostic criteria for TMD Axis I (RDC/TMD)~* duration of TMD pain ≥ 3 months~* self-assessed average myofascial-TMD pain intensity of ≥ 30 mm on a 100-mm visual analogue scale (VAS) during one week prior to examination~* familiar pain upon digital palpation of the masseter and/or the temporalis muscles.~* The patients remain included with one or several co-diagnoses of; a) disc displacement with or without reduction, b) osteoarthrosis in the any of the temporomandibular joints (TMJ), and c) episodic or chronic tension type headache~Exclusion Criteria:~* diagnosed systemic muscular or joint diseases (e.g. fibromyalgia, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis)~* whiplash associated disorder~* neuropathic pain or neurological disorders (e.g. myasthenia gravis, orofacial dystonia)~* history of psychiatric disorders~* pain of dental origin~* use of muscle relaxants or any medication that might influence the response to pain~* pregnancy or lactation~* known hypersensitivity to granisetron

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Granisetron (Type: EXPERIMENTAL): Granisetron (Kytril®; 1 mg/mL, Roche, Stockholm, Sweden) is injected into a maximum of six muscle sites in each patient. The most painful sites to palpation of the masticatory muscles is chosen, either in the same muscle (maximum 3 sites per muscle) or in a different. The injected volume into each site is0.5 mL, hence the maximum dose of granisetron a patient can receive is 3 mg per treatment. This is repeated after one and two weeks.
- Control (placebo) (Type: PLACEBO_COMPARATOR): Placebo (isotonic saline (NaCl); 0.9 mg/mL, Fresenius Kabi, Uppsala, Sweden) is injected into a maximum of six muscle sites in each patient. The most painful sites to palpation of the masticatory muscles is chosen, either in the same muscle (maximum 3 sites per muscle) or in a different. The injected volume into each site is 0.5 mL. This is repeated after one and two weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Atorvastatin 10 mg Versus 40 mg in Eight Months Follow-up Coronary Flow Reserve and Bone Marrow Stem Cell Mobilization in Patients With Acute Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years and above~* Gender eligible for study both~* Patients with acute myocardial infarction requiring sirolimus-eluting stent implantation~* Acute myocardial infarction affecting proximal to mid coronary arteries~* No lesions greater than 50 percent diameter stenosis distal to the stent implantation~* Patients with informed consent~Exclusion Criteria:~* Left main lesion~* Killip Class IV acute myocardial infarction~* Patients with current use of any statin~* Tortuous lesion with difficult intracoronary Doppler wiring~* Acute myocardial infarction affecting distal coronary arteries~* Acute myocardial infarction affecting branching coronary arteries~* The use of thiazolidinediones within 3 months~* Previous history of PCI or bypass surgery on infarct-related coronary artery~* Patients with any contraindications to the treatment of atorvastatin~* Pregnant or lactating patients~* Chronic alcohol or drug abuse~* Hepatic dysfunction (3 times above upper normal limit 5 days after AMI)~* Renal dysfunction (Creatinine greater than 2.0 mg/dL)~* Severe Heart failure (EF less than 25 percent)~* Expected life expectancy of less thna 1 year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 4 Study in the Elderly Patients With T2DM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 Diabetes Mellitus (DM) patients aged 65 to 80 years, willing to perform SMBG in case of symptomatic hypoglycemia.~* HbA1c: 6.5 to 8.5 % with max tolerated dose of metformin monotherapy for at least 3 months.~Exclusion Criteria:~* Age \> 80 yrs~* BMI \< 22 and ≥ 45 kg/m2~* Secondary T2 DM~* Hepatic failure, moderate/severe renal failure (Cl \< 50 ml/min) and CHF III \& IV~* ASAT / ALAT \> 3 ULN, creatinine clearance \< 50 ml/min Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Vildagliptin (Type: EXPERIMENTAL): None
- other Oral Antidiabetic Drug in a different therapeutic class (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Botox and Suction-Curettage for Treatment of Excessive Underarm Sweating (Axillary Hyperhidrosis)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 18 to 65~* BMI 18.5 - 29.99~* Diagnosis of bilateral axillary hyperhidrosis refractory to previous topical therapies~* Subject is in good health~* Subject has the willingness and ability to understand and provide informed consent~Exclusion Criteria:~* Under age 18 or over age 65~* Pregnancy or lactating~* BMI ≥ 30 or ≤18.4~* Subjects who have undergone axillary suction/curettage any time in the past~* Subjects who have undergone axillary BT-A injections in the past year~* Subjects currently taking blood thinners or who have had chemotherapy or radiation within the last 6 months~* Subjects with a history of a bleeding disorder~* Subjects with an open, non-healing sore or infection near site of procedure~* Subjects with allergies to iodine, starch powder, albumin, or any botulinum toxin product

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Suction-Curettage (Type: ACTIVE_COMPARATOR): None
- Botox (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent obtained before entering the trial.~* Male and female 18-65 years of age.~* A clinical history of relevant rhinitis or rhinoconjunctivitis (with/without concurrent asthma) to grass pollen of at least one year prior to trial entry.~* Documented positive specific IgE against grass pollen (IgE ≥ Class 2) into the 5 previous years.~* Positive Skin Prick Test response (wheal diameter ≥ 3 mm) to Phleum pratense.~* Negative pregnancy test for childbearing potential females.~* Willing and able to comply with the trial protocol regimen.~Exclusion Criteria:~* Previous treatment by immunotherapy with grass allergen extracts.~* A clinical history of symptomatic perennial allergic rhinitis or asthma.~* Patients with contraindications for immunotherapy as established by the IT subcommittee of the EAACI or in the Summary of Products Characteristics of GRAZAX®.~* Positive pregnancy test (in fertile females).~* Being immediate family of the investigator or trial staff.~* A mental condition rendering the subject unable to understand the nature, scope and possible consequences of the trial, and/or evidence of an uncooperative attitude.~* Unlikely to be able to complete the trial, for any reason, or likely to move, or travel for extended periods of time during the trial period.~* Use of an investigational drug within 30 days or 5 half-lives, whichever is longest, prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- GRAZAX (Type: EXPERIMENTAL): GRAZAX

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age or older~2. Diagnosis of open angle glaucoma or ocular hypertension in both eyes~3. Unmedicated intraocular pressure \>20mmHg and \<36mmHg in both eyes at 2 qualification visits. Both eyes had to qualify at all qualification visits~4. Corrected visual acuity equivalent to 20/200 Snellen or better~5. Able to give informed consent and follow study instructions~Exclusion Criteria:~1. Clinically significant ocular disease~2. Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure or narrow angles~3. Unmedicated Intraocular pressure ≥36mmHg~4. Use of more than 2 ocular hypotensive medications within 30 days of screening~5. Known hypersensitivity to any component of the formulation~6. Previous glaucoma surgery or refractive surgery~7. Ocular trauma within 6 months prior to screening~8. Any ocular surgery or non-refractive laser treatment within 3 months prior to screening~9. Recent or current ocular infection or inflammation in either eye~10. Used ocular medication in either eye of any kind within 30 days of screening~11. Mean central corneal thickness \>620µm at screening~12. Any abnormality preventing reliable applanation tonometry of either eye~13. Clinically significant abnormalities in lab tests at screening~14. Clinically significant systemic disease~15. Participation in any investigational study within 60 days prior to screening~16. Used any systemic medication that could have a substantial effect on intraocular pressure within 30 days prior to screening~17. Women who are pregnant, nursing, planning a pregnancy or not using a medically acceptable form of birth control

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PG324 Ophthalmic Solution 0.02%/0.005% (Type: EXPERIMENTAL): Fixed combination of netarsudil 0.02%, latanoprost 0.005% ophthalmic solution
- AR-13324 Ophthalmic Solution 0.02% (Type: ACTIVE_COMPARATOR): Netarsudil 0.02% ophthalmic solution
- Latanoprost Ophthalmic Solution 0.005% (Type: ACTIVE_COMPARATOR): Latanoprost 0.005% ophthalmic solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have cytologic or histologic confirmation of carcinoma arising in the pancreas.~* Patients must be deemed resectable or borderline resectable based on criteria in section 4.2 prior to registration.~* Patients must have an expected life expectancy of at least 12 weeks and a Zubrod performance status of \< 2.~* Patients must have adequate organ function defined as follows: absolute neutrophil count of \> 1500/mm3, platelets \> 100,000/mm3, serum Cr \< 1.5 mg/dl, total bilirubin \< 3.0 mg/dl with relief of biliary obstruction if present (PTC tube or endobiliary stent).~* Patients must be free of other active systemic malignancy, ongoing infection, including HIV infection, or any other serious uncontrolled, concomitant systemic disorders or psychiatric condition that would interfere with the safe delivery of protocol therapy.~* Patients must be aware of the investigational nature of the therapy and provide written informed consent.~* Patients must have no history of previous chemotherapy for pancreatic cancer or any abdominal radiation therapy.~* Patients must not have used any investigational agent in the month before enrollment into the study.~Exclusion Criteria:~* Patients with neuroendocrine tumors are excluded.~* Patients with preexisting peripheral neuropathy \> grade 2 are ineligible.~* Pregnant or nursing women are ineligible and patients of reproductive potential must agree to use an effective contraceptive method during participation in this trial and for 6 months after trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oxaliplatin & gemcitabine with radiation (Type: EXPERIMENTAL): This study will examine a sequence of treatments including pre-operative chemotherapy and radiation, surgery and post-operative chemotherapy for resectable pancreatic cancer.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete